遠大醫藥(00512.HK):集團全球創新產品STC3141在比利時獲批開展治療膿毒症Ib期臨牀研究
格隆匯4月26日丨遠大醫藥(00512.HK)發佈公吿,集團全資擁有附屬公司Grand Medical Pty Ltd(一間集團在澳洲設立的創新藥研發中心)正在開發的用於治療膿毒症的全球創新藥物STC3141,日前已獲得批准在比利時開展用於治療膿毒症的Ib期臨牀研究。
此前,STC3141已在澳洲完成了Ia期健康志願者的臨牀研究,初步確定了藥物的人體安全性及代謝特性;並已進入Ib期臨牀研究,於2020年12月完成首例患者給藥。此次STC3141在比利時獲批開展用於治療膿毒症的Ib期臨牀研究,一方面將進一步評估藥物在膿毒症患者中的安全性及代謝特性,另一方面也加速了STC3141在全球範圍內的研發佈局和上市進度。
公吿表示,集團一直高度重視創新產品和先進技術的研發,以患者需求為核心,以科技創新為驅動,針對尚未滿足的臨牀需求,加大對全球創新產品和先進技術的投入,豐富和完善產品管線及產業佈局,採用“全球化運營佈局,雙循環經營發展”策略,形成國內國際雙循環聯動發展並相互促進的新格局,充分發揮集團的產業優勢和研發實力,快速將科技創新產品落地上市,為全球患者提供更先進更多樣的治療方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.